ImotopesTM: a radically new approach to the treatment of autoimmune diseases – now entering Ph.2 testing in type 1 diabetes
Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe chronic autoimmune diseases. Founded as a spin-off of the Catholic University of Leuven in 2011, Imcyse subsequently relocated to Liège, Belgium.
The Imcyse technology platform has the potential to address a wide range of indications in the vast field of immunology. It is based on the discovery of modified synthetic peptides – ImotopesTM, which specifically block improper immune responses. Thus representing a next generation, potentially curative approach to severe chronic autoimmune diseases for which there is no satisfactory therapeutic alternative.
With an initial focus on type 1 diabetes (T1D) our lead candidate, IMCY-0098, is a novel insulin-based ImotopeTM. T1D is an autoimmune disease in which beta-cells are destroyed due to an inadequate immune response. Thereby, the pancreas stops producing insulin, the hormone that controls blood-sugar levels. With IMCY-0098, we aim to intervene early in the autoimmune response to stop the destruction of beta-cells, by this means, the ability of the pancreas to naturally produce insulin is restored.
In a phase 1 study, IMCY-0098 was found to be safe and well tolerated; early signs of efficacy could also be detected. Preparations are now underway for a phase 2 study program – IMPACT – with leading T1D KOL Prof. Dr. Chantal Mathieu as principal investigator. The study is expected to begin in September 2020.
As a proud member of INNODIA, a global network of academic institutions, industrial partners, patient organizations and a small sized enterprise bringing their knowledge and experience together to fight T1D, Imcyse aims to leverage this private public partnership to gain greater access to T1D patient populations, a platform for scientific knowledge exchange and technical approaches to refine treatment with ImotopesTM as a safe and effective therapy for patients with early T1D.
Denis Bedoret was appointed Chief Executive Officer of Imcyse S.A. in September 2020. He commented, “I am thrilled to join Imcyse in the run-up to the start of its phase 2 type 1 diabetes study. Building on promising phase 1 clinical data, Imotope™ technology represents a revolutionary therapeutic option for patients with this and many other severe, chronic autoimmune diseases. With the drive and commitment of this team of talented and passionate innovators, I am confident we have what it takes to successfully advance the already encouraging trajectory of Imcyse.”